Advances in apheresis therapy for glomerular diseases
Search this article
Abstract
This article is an overview of the immunomodulatory effects of apheresis in renal diseases, especially primary and secondary glomerulonephritis, and the clinical evidence for the efficacy of apheresis therapy. Permeability factor(s) derived from circulating T cells are speculated to have a crucial role in the proteinuria of nephrotic syndrome (NS). Plasma exchange (PE); immunoadsorption plasmapheresis (IAPP), using protein A sepharose cartridges; low-density lipoprotein apheresis; and lymphocytapheresis (LCAP) have been used to remove such factors or pathogenic T cells. Other glomerular diseases induced by specific antibodies such as anti-glomerular basement membrane antibodies, anti-neutrophil cytoplasmic antibodies, and immune-complexes have also been treated with PE, double-filtration plasmapheresis, IAPP, and LCAP. Recommendations, based on the evidence from recent randomized controlled studies, have been established in apheresis therapy for various glomerular diseases. © 2007 Japanese Society of Nephrology.
Journal
-
- Clinical and Experimental Nephrology
-
Clinical and Experimental Nephrology 11 (2), 122-127, 2007-06-01
日本腎臓学会 = Japanese Society of Nephrology
- Tweet
Details 詳細情報について
-
- CRID
- 1050282810927534592
-
- NII Article ID
- 10024140463
-
- NII Book ID
- AA11126935
-
- ISSN
- 13421751
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- IRDB
- CiNii Articles